Bayard Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 18-07-2024
- Paid Up Capital ₹ 0.10 M
as on 18-07-2024
- Company Age 11 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.11 M
as on 18-07-2024
- Revenue 41.93%
(FY 2022)
- Profit 84.07%
(FY 2022)
- Ebitda 85.49%
(FY 2022)
- Net Worth 49.97%
(FY 2022)
- Total Assets 19.62%
(FY 2022)
About Bayard Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.11 M.
Nallattu Ajeesh, Kabeer Basheer, and Dileep Krishnan serve as directors at the Company.
- CIN/LLPIN
U51397TN2013PTC091857
- Company No.
091857
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bayard Pharmaceuticals Private Limited offer?
Bayard Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement.
Who are the key members and board of directors at Bayard Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nallattu Ajeesh  | Director | 26-Jun-2013 | Current |
| Kabeer Basheer | Director | 26-Jun-2013 | Current |
| Dileep Krishnan | Director | 26-Jun-2013 | Current |
Financial Performance and Corporate Structure Insights of Bayard Pharmaceuticals.
Bayard Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 41.93% increase. The company also saw a substantial improvement in profitability, with a 84.07% increase in profit. The company's net worth Soared by an impressive increase of 49.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bayard Pharmaceuticals?
In 2023, Bayard Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Oct 2021 | ₹1.41 M | Open |
Others Creation Date: 30 Jan 2021 | ₹2.00 M | Open |
Others Creation Date: 31 Dec 2020 | ₹4.70 M | Open |
How Many Employees Work at Bayard Pharmaceuticals?
Bayard Pharmaceuticals has a workforce of 21 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bayard Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bayard Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
